In EGFR-mutated NSCLC, Magnuson et al. performed a multi-institutional analysis to evaluate multidisciplinary optimal management options for patients with BrMs managed with the first-generation TKI erlotinib [142]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.